Artivion (NYSE:AORT) SVP Marshall Stanton Sells 2,149 Shares

Artivion, Inc. (NYSE:AORT) SVP Marshall Stanton sold 2,149 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total transaction of $81,189.22. Following the completion of the transaction, the senior vice president directly owned 60,097 shares in the company, valued at $2,270,464.66. This represents a 3.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Artivion Stock Performance

Shares of NYSE:AORT traded down $0.21 during trading on Wednesday, hitting $38.41. 460,494 shares of the company traded hands, compared to its average volume of 509,518. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49. The business’s fifty day moving average is $41.42 and its 200-day moving average is $42.92. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of 61.30 and a beta of 1.60. Artivion, Inc. has a one year low of $21.97 and a one year high of $48.25.

Artivion (NYSE:AORT) last posted its earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The company had revenue of $118.30 million for the quarter, compared to analysts’ expectations of $116.42 million. Artivion’s revenue was up 19.2% compared to the same quarter last year. As a group, equities analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Artivion

Several institutional investors have recently added to or reduced their stakes in AORT. Invesco Ltd. raised its stake in shares of Artivion by 211.9% in the fourth quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock valued at $50,228,000 after acquiring an additional 748,119 shares during the last quarter. XTX Topco Ltd acquired a new stake in Artivion during the 4th quarter worth $746,000. Susquehanna Portfolio Strategies LLC raised its position in shares of Artivion by 21.5% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 40,542 shares of the company’s stock valued at $1,849,000 after acquiring an additional 7,186 shares during the last quarter. Occudo Quantitative Strategies LP acquired a new position in shares of Artivion in the 4th quarter valued at $248,000. Finally, Millennium Management LLC boosted its position in shares of Artivion by 1.0% in the 4th quarter. Millennium Management LLC now owns 91,816 shares of the company’s stock worth $4,188,000 after purchasing an additional 893 shares during the last quarter. 86.37% of the stock is owned by institutional investors.

Trending Headlines about Artivion

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Analysts remain constructive — consensus rating is “Moderate Buy” with several buy/outperform notes and mid‑to‑high price targets that support investor demand. Artivion Receives Consensus Rating
• Positive Sentiment: Management will present at the Oppenheimer Healthcare MedTech & Services Conference (virtual fireside chat), giving the company an opportunity to update investors on growth drivers, product progress and commercial milestones. Conferences can re‑ignite buying interest if guidance or pipeline commentary is favorable. Artivion to Participate in Oppenheimer Conference
• Positive Sentiment: Large institutional investors have been adding exposure (Invesco and others increased stakes), which can provide a steady bid and signals confidence from professional investors. MarketBeat – Artivion Institutional Activity
• Neutral Sentiment: Recent quarterly results beat revenue and EPS estimates and showed strong year‑over‑year revenue growth; that supports the bull case but may already be reflected in the share price and analyst upgrades. MarketBeat – Artivion Earnings Summary
• Negative Sentiment: Multiple senior insiders sold stock over March 2–4 (including the CEO and several EVPs/SVPs). A concentrated block of insider sales often weighs on sentiment even when executives retain large holdings — markets can interpret it as opportunistic liquidity or as a signal of limited near‑term confidence. Insider Trades Alert

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Citizens Jmp raised their target price on shares of Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $58.00 target price on shares of Artivion in a report on Monday, February 2nd. Canaccord Genuity Group lowered their price objective on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. Oppenheimer reiterated an “outperform” rating and issued a $50.00 target price on shares of Artivion in a report on Friday, November 7th. Finally, Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $48.97.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.